| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/15/2004 | WO2003062191A8 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 01/15/2004 | WO2003060072A3 Recombinant polypeptides |
| 01/15/2004 | WO2003019146A3 High throughput screening assays using fatty acid synthetic enzymes |
| 01/15/2004 | WO2002096866A3 Thiolalkyl benzoic acid derivatives |
| 01/15/2004 | WO2002072607A3 Soluble heterodimeric cytokine receptor |
| 01/15/2004 | WO2002060935A8 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences |
| 01/15/2004 | WO2002042777A3 Modulation of the interaction between evh1 domains |
| 01/15/2004 | US20040010148 Antiinflammatory agents, antiallergens, antiproliferative agents, immunosuppressants, antidiabetic agents, cardiovascular disorders |
| 01/15/2004 | US20040010147 Cyclic amine compounds and pharmaceutical composition containing the same |
| 01/15/2004 | US20040010141 Antiinflammatory agents; anticancer agents; rheumatic disorders; cardiovascular disorders |
| 01/15/2004 | US20040010134 Albumin fusion proteins |
| 01/15/2004 | US20040010124 CD16A binding proteins and use for the treatment of immune disorders |
| 01/15/2004 | US20040010029 Also benzothiophene derivatives; treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and infections; modulating T helper cells, Th1/ Th2, and inhibiting the transcription of IL-4 |
| 01/15/2004 | US20040010023 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 01/15/2004 | US20040010020 Trifluoromethyl-substituted nitrogen compounds; treating type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma |
| 01/15/2004 | US20040010019 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 01/15/2004 | US20040010013 Cannabinoid receptor ligands |
| 01/15/2004 | US20040010010 Melanocortin receptor ligands |
| 01/15/2004 | US20040010008 Piperidine derivatives useful as CCR5 antagonists |
| 01/15/2004 | US20040009998 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 01/15/2004 | US20040009996 4-(1,2- or 2,1-benzoxazol-5-yl)-2-aminopyrimidines |
| 01/15/2004 | US20040009995 Treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade |
| 01/15/2004 | US20040009983 Azaindoles |
| 01/15/2004 | US20040009980 Calcilytic compounds |
| 01/15/2004 | US20040009968 Indazole compounds useful as protein kinase inhibitors |
| 01/15/2004 | US20040009966 Interleukin converting enzyme inhibitors |
| 01/15/2004 | US20040009965 Treating hyperproliferative disorders |
| 01/15/2004 | US20040009950 Secreted human proteins |
| 01/15/2004 | US20040009914 Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis |
| 01/15/2004 | US20040009905 Templates consist of cyclized peptides containing at least two residues in said cyclized peptide are joined by a naphthyl ring; and having bonded to it a linear peptide |
| 01/15/2004 | US20040009901 Identifying and administering an agent that enhances NADPH oxidase activity; diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency |
| 01/15/2004 | US20040009895 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 01/15/2004 | US20040009248 Method for improving the cell protection |
| 01/15/2004 | US20040009244 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 01/15/2004 | US20040009240 For treatment of squamous cell carcinomas, tumours and other metastatic states (lung cancer) |
| 01/15/2004 | US20040009221 Particularly ketorolac; pain treatment; core, a drug layer (which comprises the drug, a binder, and a disintegrant), a protecting layer, and an enteric coating |
| 01/15/2004 | US20040009217 Therapeutic liposome composition and method |
| 01/15/2004 | US20040009216 Administering liposomes comprising phospholipids and an aqueous layer, said liposomes having specified average diameter; treating various cardiovascular disorders, reducing cholesterol |
| 01/15/2004 | US20040009169 Administration of agents for the treatment of inflammation |
| 01/15/2004 | US20040009167 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 01/15/2004 | US20040009163 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 01/15/2004 | DE10229070A1 Phenylderivate 5 Phenyl derivatives 5 |
| 01/15/2004 | DE10227938A1 Pharmazeutische Zubereitung, Verfahren zu ihrer Herstellung sowie deren Verwendung A pharmaceutical preparation, processes for their preparation and their use |
| 01/15/2004 | DE10226326A1 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene 9-alpha-substiuierte estratrienes as selective estrogens effective |
| 01/15/2004 | CA2492122A1 Novel tricyclic spiropiperidines or spiropyrrolidines |
| 01/15/2004 | CA2492037A1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 01/15/2004 | CA2492026A1 New pharmaceutical compositions based on new anticholinergics and pde-iv inhibitors |
| 01/15/2004 | CA2492010A1 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | CA2491994A1 Modulators of the glucocorticoid receptor |
| 01/15/2004 | CA2491848A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 01/15/2004 | CA2491464A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | CA2491451A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 01/15/2004 | CA2491445A1 Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects |
| 01/15/2004 | CA2491406A1 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | CA2491321A1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | CA2491127A1 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2490463A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough |
| 01/15/2004 | CA2490097A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | CA2489402A1 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/15/2004 | CA2489398A1 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 01/15/2004 | CA2488736A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 01/14/2004 | EP1380593A1 Soluble rage protein |
| 01/14/2004 | EP1380579A1 Novel physiologically active substances |
| 01/14/2004 | EP1380576A1 Novel 1h-indazole compound |
| 01/14/2004 | EP1380571A1 Compounds useful for treating allergic and inflammatory diseases |
| 01/14/2004 | EP1380562A1 Carboxylic acid derivative and salt thereof |
| 01/14/2004 | EP1380296A1 Hsp inductor |
| 01/14/2004 | EP1380294A1 Preventive/remedial agent for inflammatory disease in oral-cavity mucosa and the like |
| 01/14/2004 | EP1380290A1 Cross-beta structure pathway and its therapeutic relevance |
| 01/14/2004 | EP1379679A2 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 01/14/2004 | EP1379662A2 Sulfatases and methods of use thereof |
| 01/14/2004 | EP1379654A2 Intracellular signaling molecules |
| 01/14/2004 | EP1379630A2 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |
| 01/14/2004 | EP1379550A2 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences |
| 01/14/2004 | EP1379542A2 Treatment of tumours |
| 01/14/2004 | EP1379533A2 Novel cyclo azaphospha hydrocarbons |
| 01/14/2004 | EP1379528A1 Pyrazolopyrimidines as therapeutic agents |
| 01/14/2004 | EP1379523A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 01/14/2004 | EP1379520A1 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| 01/14/2004 | EP1379519A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379516A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 01/14/2004 | EP1379513A1 Prodrugs of cox-2 inhibitors |
| 01/14/2004 | EP1379507A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS |
| 01/14/2004 | EP1379504A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors |
| 01/14/2004 | EP1379503A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379495A2 Ligands of the alpha-v-beta 6 integrin |
| 01/14/2004 | EP1379494A1 Fused bicyclic or tricyclic amino acids |
| 01/14/2004 | EP1379279A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine |
| 01/14/2004 | EP1379260A2 Methods for treating the inflammatory component of a brain disorder |
| 01/14/2004 | EP1379257A2 Prodrugs of anticancer agents employing substituted aromatic acids |
| 01/14/2004 | EP1379252A2 Nociceptin analogs |
| 01/14/2004 | EP1379249A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 01/14/2004 | EP1379247A1 Agent for topical ophthalmic treatment of ocular inflammatory diseases |
| 01/14/2004 | EP1379246A1 Nociceptin analogs |
| 01/14/2004 | EP1379241A1 Compounds and methods |
| 01/14/2004 | EP1379240A1 Compounds and methods |
| 01/14/2004 | EP1379232A2 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| 01/14/2004 | EP1379230A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |